Magrolimab + Bavencio: "The combination of magrolimab + avelumab has a tolerable safety profile and no maximum tolerated dose was reached"; Solid tumor (Forty Seven) - Mar 26, 2020 - ASCO-SITC 2020: "Ovarian cancer pt had SD by RECIST but had -46% reduction in tumor size and was a PR by irRECIST and GCIG CA-125 criteria and remains on treatment for 9+ months"
P1 data
|